Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression

Affiliations

01 January 2022

-

doi: 10.1016/j.bbi.2021.07.016


Abstract

Alzheimer's disease (AD) pathology is characterized by amyloid-β (Aβ) deposition and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Monocytes have been recently shown to play a major role in modulating Aβ pathology, and thereby have been pointed as potential therapeutic targets. However, the main challenge remains in identifying clinically relevant interventions that could modulate monocyte immune functions in absence of undesired off-target effects. Erythropoietin (EPO), a key regulator of erythrocyte production, has been shown to possess immunomodulatory potential and to provide beneficial effects in preclinical models of AD. However, the transition to use recombinant human EPO in clinical trials was hindered by unwanted erythropoietic effects that could lead to thrombosis. Here, we used a recently identified non-erythropoietic analogue of EPO, ARA 290, to evaluate its therapeutic potential in AD therapy. We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, represented by young APP/PS1 mice. Our findings indicate that ARA 290 early treatment decelerated Aβ pathology progression in APP/PS1 mice while improving cognitive functions. ARA 290 potently increased the levels of total monocytes by specifically stimulating the generation of Ly6CLow patrolling subset, which are implicated in clearing Aβ from the cerebral vasculature, and subsequently reducing overall Aβ burden in the brain. Moreover, ARA 290 increased the levels of monocyte progenitors in the bone marrow. Using chimeric APP/PS1 mice in which Ly6CLow patrolling subset are selectively depleted, ARA 290 was inefficient in attenuating Aβ pathology and ameliorating cognitive functions in young animals. Interestingly, ARA 290 effects were compromised when delivered in a late-onset model, represented by aged APP1/PS1. In aged APP/PS1 mice in which AD-like pathology is at advanced stages, ARA 290 failed to reverse Aβ pathology and to increase the levels of circulating monocytes. Our study suggests that ARA 290 early systemic treatment could prevent AD-like progression via modulation of monocyte functions by specifically increasing the ratio of patrolling monocytes.

Keywords: Alzheimer’s disease; Amyloid-beta; Bone marrow transplantation; Erythropoietin-derived peptides; Immunomodulation; Memory; Monocytes.


Similar articles

Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner.

Lecordier S, Pons V, Rivest S, ElAli A.Front Immunol. 2022 Jan 31;12:813536. doi: 10.3389/fimmu.2021.813536. eCollection 2021.PMID: 35173711 Free PMC article.

ABCA7 Deficiency Accelerates Amyloid-β Generation and Alzheimer's Neuronal Pathology.

Sakae N, Liu CC, Shinohara M, Frisch-Daiello J, Ma L, Yamazaki Y, Tachibana M, Younkin L, Kurti A, Carrasquillo MM, Zou F, Sevlever D, Bisceglio G, Gan M, Fol R, Knight P, Wang M, Han X, Fryer JD, Fitzgerald ML, Ohyagi Y, Younkin SG, Bu G, Kanekiyo T.J Neurosci. 2016 Mar 30;36(13):3848-59. doi: 10.1523/JNEUROSCI.3757-15.2016.PMID: 27030769 Free PMC article.

Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.

Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F.Exp Gerontol. 2000 Sep;35(6-7):831-41. doi: 10.1016/s0531-5565(00)00149-2.PMID: 11053674 Review.

Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice.

Chen Y, Zhao S, Fan Z, Li Z, Zhu Y, Shen T, Li K, Yan Y, Tian J, Liu Z, Zhang B.Alzheimers Res Ther. 2021 Feb 9;13(1):40. doi: 10.1186/s13195-020-00761-9.PMID: 33563332 Free PMC article.

Recent Advances in the Modeling of Alzheimer's Disease.

Sasaguri H, Hashimoto S, Watamura N, Sato K, Takamura R, Nagata K, Tsubuki S, Ohshima T, Yoshiki A, Sato K, Kumita W, Sasaki E, Kitazume S, Nilsson P, Winblad B, Saito T, Iwata N, Saido TC.Front Neurosci. 2022 Mar 31;16:807473. doi: 10.3389/fnins.2022.807473. eCollection 2022.PMID: 35431779 Free PMC article. Review.


Cited by

Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice.

Xu G, Zou T, Deng L, Yang G, Guo T, Wang Y, Niu C, Cheng Q, Yang X, Dong J, Zhang J.Front Pharmacol. 2022 Aug 15;13:896601. doi: 10.3389/fphar.2022.896601. eCollection 2022.PMID: 36046815 Free PMC article.

Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner.

Lecordier S, Pons V, Rivest S, ElAli A.Front Immunol. 2022 Jan 31;12:813536. doi: 10.3389/fimmu.2021.813536. eCollection 2021.PMID: 35173711 Free PMC article.


KMEL References